Emergence of neurophysiological biomarkers of Alzheimer disease

Lazzaro, Vincenzo Di

doi:10.1136/jnnp-2018-318867

Cited by 7 publications

(3 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TMS has the advantage that it can be carried out concomitantly in the outpatient visit, being noninvasive, relatively non–time consuming, and rather inexpensive. For these reasons, beyond resulting as a marker with diagnostic accuracy values comparable to those of well‐established biomarkers, TMS might represent a reliable and accessible screening tool, considering the exponential increase in the prevalence of people living with dementia…”

Section: Discussionmentioning

confidence: 99%

“…AD = Alzheimer disease; Cases = AD, FTD, or DLB; DLB = dementia with Lewy bodies; FTD = frontotemporal dementia; HC = healthy controls; non-FTD = AD or DLB. accessible screening tool, 55 considering the exponential increase in the prevalence of people living with dementia. 1 The strength of the present work relies on the very large sample size, with a multicenter enrollment, and the machine-learning approach to data analysis to obtain the highest possible values of diagnostic accuracy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias

Benussi

Grassi

Palluzzi

et al. 2020

Annals of Neurology

Self Cite

View full text Add to dashboard Cite

Objective Transcranial magnetic stimulation (TMS) has been suggested as a reliable, noninvasive, and inexpensive tool for the diagnosis of neurodegenerative dementias. In this study, we assessed the classification performance of TMS parameters in the differential diagnosis of common neurodegenerative disorders, including Alzheimer disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Methods We performed a multicenter study enrolling patients referred to 4 dementia centers in Italy, in accordance with the Standards for Reporting of Diagnostic Accuracy. All patients underwent TMS assessment at recruitment (index test), with application of reference clinical criteria, to predict different neurodegenerative disorders. The investigators who performed the index test were masked to the results of the reference test and all other investigations. We trained and tested a random forest classifier using 5‐fold cross‐validation. The primary outcome measures were the classification accuracy, precision, recall, and F1 score of TMS in differentiating each neurodegenerative disorder. Results A total of 694 participants were included, namely 273 patients diagnosed as AD, 67 as DLB, and 207 as FTD, and 147 healthy controls (HC). A series of 3 binary classifiers was employed, and the prediction model exhibited high classification accuracy (ranging from 0.89 to 0.92), high precision (0.86–0.92), high recall (0.93–0.98), and high F1 scores (0.89–0.95) in differentiating each neurodegenerative disorder. Interpretation TMS is a noninvasive procedure that reliably and selectively distinguishes AD, DLB, FTD, and HC, representing a useful additional screening tool to be used in clinical practice. Ann Neurol 2020;87:394–404

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias

Benussi

Grassi

Palluzzi

et al. 2020

Annals of Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Alzheimer’s disease (AD) is a progressive neurodegenerative disorder representing the most common cause of dementia in the elderly. The hallmarks of AD include senile plaques induced by amyloid-β (Aβ) protein deposits, neurofibrillary tangles formed by aggregates of hyperphosphorylated tau proteins and neuronal cell loss in specific position within the brain (Di Lazzaro, 2018). Soluble Aβ and prefibrillar oligomers have been recognized as early and key factors in AD-related synaptic dysfunction.…”

Section: Introductionmentioning

confidence: 99%

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease

Zhang

Zhao

Zhang

et al. 2019

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The pathological features of Alzheimer’s disease (AD) include senile plaques induced by amyloid-β (Aβ) protein deposits, neurofibrillary tangles formed by aggregates of hyperphosphorylated tau proteins and neuronal cell loss in specific position within the brain. Recent observations have suggested the possibility of an association between AD and cellular prion protein (PrP C ) levels. PrP C is a high affinity receptor for oligomeric Aβ and is important for Aβ-induced neurotoxicity and thus plays a critical role in AD pathogenesis. The determination of the relationship between PrP C and AD and the characterization of PrP C binding to Aβ will facilitate the development of novel therapies for AD.

show abstract

The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts

et al. 2022

View full text Add to dashboard Cite

Emergence of neurophysiological biomarkers of Alzheimer disease

Cited by 7 publications

References 7 publications

Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias

Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease

The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts

Contact Info

Product

Resources

About